--


Scan for WeChat

Sorafenat 200mg Tablets : 印度 索拉非尼

Medicine Detail


Brand Name: Sorafenat 200mg 

Active Ingredient: Sorafenib Tosylate 200mg 

Manufactured by: Natco Pharma Ltd. (India) 

Strength: 200mg 

Form: Tablets 

Packing: Pack of 120 Tablets 





多吉美主要是抑制作用于肿瘤细胞和肿瘤血管上的丝氨酸/苏氨酸激酶(Raf)和酪氨酸激酶,这两种激酶会影响肿瘤细胞增生及血管生成,并且抑制肿瘤的生长。


多吉美的收益如何?

1,肝癌:临床数据显示,服用多吉美的患者中位总生计期为10.7个月,而安慰剂对照的中位总生计期为7.9个月。多吉美降低了肝癌患者31%的死亡率。

2,肾癌:肾癌晚期患者在服用多吉美后中位无疾病进展生存时间(PFS)为29-41周;肿瘤控制率高达75.1%-80%;中位PFS长达40-42周。

3,甲状腺癌:多吉美使患者疾病无进展的持续时间(无进展生存期)增加41%。至少有一半多吉美用药患者的无进展生存期增加10.8个月,根据安慰剂用药患者的无进展生存期增加至少5.8个月。


Write a review

Note: HTML is not translated!
    Bad           Good
Captcha

Tags: 索拉非尼印度, 肾癌药, 多吉美200mg

Medical Disclaimer

We at MedsDelta: Trusted Medicine Supplier has come up with some facts and knowledge sourced from Internet and practitioners’ guidance. Rights, Service mark/Hallmark, Trade names of each medicine associated with the respected manufacturing Organisations. MedsDelta do not provide any medical opinion, body diagnose or treatment through their site. One should always take advice of the prescribed practitioner or doctor for any medical guidance and recommendation of any medicine they purchase. This is determined for Patients, Clinics, Doctors, Hospitals, Medical Institutions, Wholesale Supplier, Pharmacies, Resellers etc.